Straits Times Index
3,404.47 -6.34 (-0.19%) S&P 500
5,567.19 +30.17 (+0.54%) Dow
39,375.87 +67.87 (+0.17%) Nasdaq
18,352.76 +164.46 (+0.90%) Bitcoin USD
57,103.02 -314.16 (-0.55%) CMC Crypto 200
1,226.91 +60.80 (+5.22%)
ARDX Jan 2025 1.000 call
| Previous close | 4.3900 |
| Open | 4.3900 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 1.00 |
| Expiry date | 2025-01-17 |
| Day's range | 4.3900 - 4.3900 |
| Contract range | N/A |
| Volume | |
| Open interest | 751 |
GlobeNewswireTo Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA
Ardelyx continues support for bipartisan legislation that would extend the exclusion of oral-only medications from entering the CMS Prospective Payment System Conference call scheduled for 8:00 AM Eastern Time WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that, in an effort to pr
- GlobeNewswire
Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data detailing educational needs related to irritable bowel syndrome with constipation (IBS-C) across healthcare disciplines was presented via a poster at the 2024 American Association of Nurse Practitioners (AANP) Annual Confere
Simply Wall St.When Will Ardelyx, Inc. (NASDAQ:ARDX) Become Profitable?
With the business potentially at an important milestone, we thought we'd take a closer look at Ardelyx, Inc.'s...
